PI3K-mTOR双重小分子抑制剂的研究进展
投稿时间:2013-03-18  修订日期:2013-04-08  点此下载全文
引用本文:陈颖,韩进松,王重庆,宋云龙,周永刚,朱驹.PI3K-mTOR双重小分子抑制剂的研究进展[J].药学实践杂志,2014,32(5):332~336,359
摘要点击次数: 1110
全文下载次数: 328
作者单位E-mail
陈颖 第二军医大学药学院药物化学教研室, 上海 200433  
韩进松 第二军医大学药学院药物化学教研室, 上海 200433  
王重庆 第二军医大学药学院药物化学教研室, 上海 200433  
宋云龙 第二军医大学药学院药物化学教研室, 上海 200433  
周永刚 解放军81医院药剂科, 江苏 南京 210002  
朱驹 第二军医大学药学院药物化学教研室, 上海 200433 zhuju@smmu.edu.cn 
中文摘要:PI3K脂激酶家族介导的细胞信号转导通路,调节细胞增殖、分化、凋亡等一系列活动,已经成为治疗肿瘤、炎症等疾病的重要靶标。近来出现了多种结构类型的该通路抑制剂,笔者总结了近年内进入临床研究的具有PI3K-mTOR双重抑制活性的小分子化合物。
中文关键词:磷脂酰肌醇3激酶-哺乳动物雷帕霉素靶蛋白  双重抑制剂  小分子  抗肿瘤
 
Review of research on dual PI3K-mTOR small molecular inhibitors
Abstract:Objective The phosphoinositide 3-kinase (PI3K) constituted an important family of lipid kinase enzymes that control a range of cellular proliferation, differentiation and apoptosis through their regulation of a network of signal transduction pathways, which had emerged as important therapeutic targets in the context of cancer and inflammation. Considerable progress had been made in the discovery and development of small molecular inhibitors targeting PI3K. Progress in dual PI3K-mTOR inhibitors, a number of which had entered early phase clinical trials over recent years was summarized.
keywords:PI3K-mTOR  dual inhibitors  small molecules  anticancer
查看全文  查看/发表评论  下载PDF阅读器
关闭

分享按钮